Micro-capsules for the sustained release of drugs

Abstract

Micro-capsules for the slow release of drugs, consisting of a lactic-co-glycolic copolymer to which a plasticizer has been incorporated and which contain a drug of pharmaceutical interested within them.

1 . A pharmaceutical preparation of microcapsules of lactic-co-glycolic copolymer which incorporates a peptide of pharmaceutical interest, characterised in that the copolymer that forms the microcapsules incorporates a citric acid ester as an additive.  
     
     
         2 . A pharmaceutical preparation of microcapsules according to  claim 1  characterised in that the citric acid ester is selected from triethyl citrate, tributyl citrate and acetyl tributyl citrate.  
     
     
         3 . A pharmaceutical preparation of microcapsules according to  claim 2  characterised in that the citric acid ester is triethyl citrate.  
     
     
         4 . A preparation according to  claim 3  characterised in that the amount of triethyl citrate contained in the preparation varies between 0.1% and 60% by weight of the copolymer.  
     
     
         5 . A pharmaceutical preparation according to  claims 1  to  4  characterised in that the percentage ratio between the lactate and glycolate units in the lactic-co-glycolic copolymer varies between 100% and lactate and 90% of glycolate, both inclusive.  
     
     
         6 . A pharmaceutical preparation according to any of the previous claims characterised in that the encapsulated peptide of pharmaceutical interest is an analogue of LHRH.  
     
     
         7 . A pharmaceutical preparation according to  claim 6  characterised in that the analogue of LHRH is selected from tryptoreline, leuprolide, gosereline, busereline or cetrorelix.  
     
     
         8 . A pharmaceutical preparation according to  claims 1  to  5  characterised in that the encapsulated peptide of pharmaceutical interest is somatostatine or an analogue thereof.  
     
     
         9 . A pharmaceutical preparation according to  claim 8  characterised in that the analogue of somatostatine is octreotide.  
     
     
         10 . A pharmaceutical preparation according to  claims 1  to  5  characterised in that the encapsulated peptide of pharmaceutical interest is an analogue of human calcitonine.  
     
     
         11 . A pharmaceutical preparation according to  claim 10  characterised in that the analogue of human calcitonine is salmon calcitonine or carbocalcitonine.